Sample size determination in bioequivalence studies using statistical assurance
Open Access
- 5 July 2019
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 85 (10) , 2369-2377
Abstract
Aims: Bioequivalence (BE) trials aim to demonstrate that the 90% confidence interval of the T/R‐ratio of the pharmacokinetic metrics between two formulations (test [T] and reference [R]) of a drug is fully included in the acceptance interval [0.80, 1.25]. Traditionally, the sample size of BE trials is based on a power calculation based on the intrasubject variability coefficient of variation (CV) and the T/R‐ratio of the metrics. Since the exact value of the T/R‐ratio is not known prior to the trial, it is often assumed that the difference between the treatments does not exceed 5%. Hence, uncertainty about the T/R‐ratio is expressed by using a fixed value for the sample size calculation. We propose to characterise the uncertainty about the T/R‐ratio by a (normal) distribution for the log(T/R‐ratio), with an assumed mean of log θ = 0.00 (i.e. θ = 1.00) and a standard deviation σu, which quantifies the uncertainty. Evaluating this distribution leads to the statistical assurance of the BE trial.Methods: The assurance of a clinical trial can be derived by integrating the power over the distribution of the input parameters, in this case, the assumed distribution of the log(T/R)‐ratio. Because it is an average power, the assurance can be interpreted as a measure of the probability of success that does not depend on a specific assumed value for the log(T/R)‐ratio. The relationship between power and assurance will be analysed by comparing the numerical outcomes.Results: Using the assurance concept, values of the standard deviation for the distribution of potential log(T/R)‐ratios can be chosen to reflect the magnitude of uncertainty. For most practical cases (i.e. when 0.95 ≤ θ ≤ 1.05), the sample size is not, or only slightly, changed when σ = |log(θ)|.Conclusion: The advantage of deriving the assurance for BE trials is that uncertainty is directly expressed as a parameter of variability.Keywords
This publication has 15 references indexed in Scilit:
- Evaluation of Mutual Drug–Drug Interaction within Geneva Cocktail for Cytochrome P450 Phenotyping using Innovative Dried Blood Sampling MethodBasic & Clinical Pharmacology & Toxicology, 2016
- Pharmacokinetics and Bioequivalence of Two Formulations of Febuxostat 40-Mg and 80-Mg Tablets: A Randomized, Open-Label, 4-Way Crossover Study in Healthy Chinese Male VolunteersPLOS ONE, 2016
- Sample size and the probability of a successful trialPharmaceutical Statistics, 2006
- Assurance in clinical trial designPharmaceutical Statistics, 2005
- Sample sizes for clinical trials with Normal dataStatistics in Medicine, 2004
- WHY ARE PHARMACOKINETIC DATA SUMMARIZED BY ARITHMETIC MEANS?Journal of Biopharmaceutical Statistics, 2000
- Common noncompartmental pharmacokinetic variables: are they normally or log-normally distributed?Journal of Biopharmaceutical Statistics, 1997
- Power of the two one-sided tests procedure in bioequivalenceJournal of Pharmacokinetics and Biopharmaceutics, 1990
- A comparison of the Two One-Sided Tests Procedure and the Power Approach for assessing the equivalence of average bioavailabilityJournal of Pharmacokinetics and Biopharmaceutics, 1987
- A special case of a bivariate non-central t-distributionBiometrika, 1965